PT  - JOURNAL ARTICLE
AU  - Sara C. Johnston
AU  - Keersten M. Ricks
AU  - Ines Lakhal-Naouar
AU  - Alexandra Jay
AU  - Caroline Subra
AU  - Jo Lynne Raymond
AU  - Hannah A. D. King
AU  - Franco Rossi
AU  - Tamara L. Clements
AU  - David Fetterer
AU  - Samantha Tostenson
AU  - Camila Macedo Cincotta
AU  - Holly R. Hack
AU  - Caitlin Kuklis
AU  - Sandrine Soman
AU  - Jocelyn King
AU  - Kristina K. Peachman
AU  - Dohoon Kim
AU  - Wei-Hung Chen
AU  - Rajeshwer S. Sankhala
AU  - Elizabeth J. Martinez
AU  - Agnes Hajduczki
AU  - William C. Chang
AU  - Misook Choe
AU  - Paul V. Thomas
AU  - Caroline E. Peterson
AU  - Alexander Anderson
AU  - Isabella Swafford
AU  - Jeffrey R. Currier
AU  - Dominic Paquin-Proulx
AU  - Linda L. Jagodzinski
AU  - Gary R. Matyas
AU  - Mangala Rao
AU  - Gregory D. Gromowski
AU  - Sheila A. Peel
AU  - Lauren White
AU  - Jeffrey M. Smith
AU  - Jay W. Hooper
AU  - Nelson L. Michael
AU  - Kayvon Modjarrad
AU  - M. Gordon Joyce
AU  - Aysegul Nalca
AU  - Diane L. Bolton
AU  - Margaret LM Pitt
TI  - A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model
AID  - 10.1101/2022.03.25.485832
DP  - 2022 Jan 01
TA  - bioRxiv
PG  - 2022.03.25.485832
4099  - http://biorxiv.org/content/early/2022/03/28/2022.03.25.485832.short
4100  - http://biorxiv.org/content/early/2022/03/28/2022.03.25.485832.full
AB  - The COVID-19 pandemic has had a staggering impact on social, economic, and public health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the etiologic agent of COVID-19) has been rapid. However, novel strategies are still necessary to slow the pandemic, and this includes new approaches to vaccine development and/or delivery, which improve vaccination compliance and demonstrate efficacy against emerging variants. Here we report on the immunogenicity and efficacy of a SARS-CoV-2 vaccine comprised of stabilized, pre-fusion Spike protein trimers displayed on a ferritin nanoparticle (SpFN) adjuvanted with either conventional aluminum hydroxide or the Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque COVID-19 model. Vaccination resulted in robust cell-mediated and humoral responses and a significant reduction of lung lesions following SARS-CoV-2 infection. The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.Competing Interest StatementThe authors have declared no competing interest.